Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0028754 (obesity)
 124,988 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Adenosine deaminase (ADA) is an enzyme of purine metabolism commonly associated with severe combined immunodeficiency disease and believed to modulate bioactivity of insulin. Its contributory role in patients with metabolic syndrome (having features such as obesity, insulin resistance, fasting hyperglycaemia, lipid abnormalities and hypertension) in South Eastern Nigeria was studied. Body mass index (BMI), fasting blood glucose (FBG), Glycated haemoglobin (GHbA1c), total cholesterol, HDL-cholesterol, LDL-cholesterol (usually impaired in metabolic syndrome) and total serum ADA activity were measured in different groups of patients with metabolic syndrome (test subjects) and apparently healthy subjects (controls). The test subjects comprised six subgroups made up of the following; obese diabetic (N=25), obese non-diabetic (N=25), Non-obese diabetic (N=25), patients with hypercholesterolaemia (N=25), LDL-cholesterolaemia (N=25) and HDL-cholesterolaemia (N=25). The results showed that the mean values of all the parameters studied (BMI, FBG, GHbA1c, total cholesterol, HDL-cholesterol and LDL-cholesterol) were higher in the test subjects than their controls. BMI did not correlate significantly with FBG, GHbA1c, and ADA in the test and control subjects respectively. The mean serum ADA activity in the test subjects of obese diabetic, obese non-diabetic and non-obese diabetic subjects was higher than in controls (p< 0.001). ADA activity was also higher in the test subjects of hypercholesterolaemia, HDL-cholesterolaemia and LDL-cholesterolaemia than in control (p< 0.001). ADA activity also correlated positively with hypercholesterolemia (r = 0.640; p<0.001), HDL-cholesterolaemia (r = 0.646; p<0.001) and LDL-cholesterolaemia (r = 0.932; p<0.001), with the highest correlation in the LDL-cholesterolaemia. In conclusion, ADA activity is increased significantly in all parameters of metabolic syndrome studied and showed a significant correlation with all the three groups of dyslipidaemic subjects studied. ADA could therefore be used in daily routine laboratory assessment of most metabolic diseases especially in obese and diabetic patients.
...
PMID:Contributory role of adenosine deaminase in metabolic syndrome. 2395 11

Adenosine deaminase (ADA) is an important regulator of insulin action. The single nucleotide polymorphism (SNP) G22A in the ADA gene decreases enzymatic activity of ADA. The aim of this study was to investigate the relationship between the SNP G22A and blood glycemic control, insulin resistance, and obesity of gestational diabetes mellitus (GDM) patients in an Iranian population. SNP G22A was determined in women with GDM (N=70) and healthy pregnant women (control, N=70) using polymerase chain reaction-restriction fragment length polymorphism. Fasting plasma glucose (FPG), hemoglobin A1C (HbA1c), plasma insulin levels and plasma lipids were measured using commercial kits. Homeostasis model of assessment for insulin resistance (HOMA-IR) was calculated. The distribution of genotypes and alleles among GDM patients was similar to that of the control group. FPG and HbA1c were significantly higher in GDM patients with GG genotype compared with GDM patients with GA+AA genotype and non-GDM patients. The frequency of GG genotype was significantly higher in obese GDM patients compared to lean GDM patients. The SNP G22A in the ADA gene was not associated with the risk of GDM in our population. GG genotype was associated with poor glycemic control and obesity in GDM patients.
...
PMID:G22A Polymorphism of Adenosine Deaminase and its Association with Biochemical Characteristics of Gestational Diabetes Mellitus in an Iranian Population. 2582 Dec 98